Cumberland Pharmaceuticals Inc (CPIX) - Total Assets
Based on the latest financial reports, Cumberland Pharmaceuticals Inc (CPIX) holds total assets worth $71.00 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Cumberland Pharmaceuticals Inc (CPIX) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Cumberland Pharmaceuticals Inc - Total Assets Trend (2005–2025)
This chart illustrates how Cumberland Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Explore Cumberland Pharmaceuticals Inc (CPIX) long-term investment share to see how much of total assets are deployed in long-term investments.
Cumberland Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Cumberland Pharmaceuticals Inc's total assets of $71.00 Million consist of 48.2% current assets and 51.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.9% |
| Accounts Receivable | $16.94 Million | 22.1% |
| Inventory | $6.23 Million | 8.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $14.03 Million | 18.3% |
| Goodwill | $914.00K | 1.2% |
Asset Composition Trend (2005–2025)
This chart illustrates how Cumberland Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Cumberland Pharmaceuticals Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cumberland Pharmaceuticals Inc's current assets represent 48.2% of total assets in 2025, a decrease from 84.5% in 2005.
- Cash Position: Cash and equivalents constituted 14.9% of total assets in 2025, down from 54.4% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 22.1% of total assets.
Cumberland Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Cumberland Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Huadong Medicine Co Ltd
SHE:000963
|
China | CN¥39.93 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
|
Celltrion Pharm Inc
KQ:068760
|
Korea | ₩745.80 Billion |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
|
China | CN¥2.53 Billion |
Cumberland Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.95 | 1.25 | 2.50 |
| Quick Ratio | 0.79 | 1.09 | 1.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.70 Million | $6.36 Million | $28.03 Million |
Cumberland Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Cumberland Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.24 |
| Latest Market Cap to Assets Ratio | 0.89 |
| Asset Growth Rate (YoY) | 1.6% |
| Total Assets | $76.82 Million |
| Market Capitalization | $68.47 Million USD |
Valuation Analysis
Near Book Valuation: The market values Cumberland Pharmaceuticals Inc's assets close to their book value (0.89x), suggesting investors view the company's assets at approximately fair value.
Positive Asset Growth: Cumberland Pharmaceuticals Inc's assets grew by 1.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Cumberland Pharmaceuticals Inc (2005–2025)
The table below shows the annual total assets of Cumberland Pharmaceuticals Inc from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $76.82 Million | +1.64% |
| 2024-12-31 | $75.58 Million | -7.57% |
| 2023-12-31 | $81.78 Million | -12.00% |
| 2022-12-31 | $92.93 Million | +10.02% |
| 2021-12-31 | $84.46 Million | -12.44% |
| 2020-12-31 | $96.46 Million | -7.73% |
| 2019-12-31 | $104.55 Million | -7.23% |
| 2018-12-31 | $112.69 Million | +20.87% |
| 2017-12-31 | $93.23 Million | -0.18% |
| 2016-12-31 | $93.40 Million | +1.62% |
| 2015-12-31 | $91.92 Million | -3.65% |
| 2014-12-31 | $95.41 Million | +8.89% |
| 2013-12-31 | $87.61 Million | -11.14% |
| 2012-12-31 | $98.59 Million | +3.22% |
| 2011-12-31 | $95.52 Million | +3.76% |
| 2010-12-31 | $92.05 Million | -11.25% |
| 2009-12-31 | $103.72 Million | +233.31% |
| 2008-12-31 | $31.12 Million | +7.61% |
| 2007-12-31 | $28.92 Million | +9.20% |
| 2006-12-31 | $26.48 Million | +160.30% |
| 2005-12-31 | $10.17 Million | -- |
About Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso… Read more